Drug Trial Radar · NCT05276570
Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Jun 29, 2022
Primary completion
Apr 16, 2025
Study completion Apr 16, 2025
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ARO-RAGE in normal healthy volunteers (NHVs) and in participants with inflammatory lung disease (asthma). In Part 1 of the study, NHVs will receive a single dose of ARO-RAGE or placebo. In Part 2 of the study, adult participants with asthma will receive 2 doses of ARO-RAGE or placebo. Additional NHVs may be randomized to receive 1 or 2 doses of ARO-RAGE or placebo at Sponsor discretion. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.
Conditions
- Asthma
Interventions
ARO-RAGEDrug
single or multiple doses of ARO-RAGE by inhalation of nebulized solution
PlaceboDrug
calculated volume to match active treatment by inhalation of nebulized solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug through the end of study (EOS; up to 113 days)
Locations
8 sites in 5 countries. Site status is shown where the registry gives one.
Research Site 1
Nedlands, Washington, Australia
Research Site 1
Auckland, New Zealand
Research Site 2
Auckland, New Zealand
Research Site 3
Auckland, New Zealand
Research Site 2
Krakow, Poland
Research Site 3
Oświęcim, Poland
Research Site 1
Barcelona, Spain
Research Site 1
Bangkok Noi, Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.